The pharmaceutical concern Grindeks achieved EUR 63.1 million in turnover in the first nine months of the year 2014, which is EUR 17.3 million or 21.5% less when compared to the nine months of last year, the company stated in its financial report submitted to the ”Nasdaq” Riga Stock Exchange, cites LETA. …read more
Source: The Baltic Course
